Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference
March 27 2017 - 4:01PM
Business Wire
Presentation to be Webcast on April 3 at
4:00 pm ET
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will present at the H.C. Wainwright 1st Annual NASH
Investor Conference in New York on April 3 at 4:00 pm ET. Dr. Luly
will present an overview of Enanta’s wholly-owned research and
development programs with a focus on EDP-305, Enanta’s FXR agonist
for non-alcoholic steatohepatitis (NASH).
A live webcast and replay of the presentation will be accessible
by visiting the “Calendar of Events” section on the “Investors”
page of Enanta’s website at www.enanta.com. The webcast replay will
be available following the presentation and will be archived for
approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs for viral infections and liver diseases. Enanta’s research
and development efforts are currently focused on the following
disease targets: non-alcoholic steatohepatitis (NASH)/ primary
biliary cholangitis (PBC), respiratory syncytial virus (RSV) and
hepatitis B virus (HBV).
Enanta has discovered novel protease inhibitors for use against
the hepatitis C virus (HCV). These protease inhibitors, developed
through Enanta’s collaboration with AbbVie, include paritaprevir,
currently marketed in AbbVie’s HCV regimens, and glecaprevir
(ABT-493), Enanta’s second protease inhibitor product, which AbbVie
is developing as part of its investigational HCV regimen of
glecaprevir/pibrentasvir (G/P) now in registration in the U.S., the
E.U. and Japan. Royalties and any further milestone payments from
this collaboration will provide funding for Enanta’s earlier
development programs, including its Phase 1 FXR agonist program for
NASH/PBC, and its preclinical programs for HBV and RSV. Please
visit www.enanta.com for more information on Enanta’s programs and
pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170327005800/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024